Your browser doesn't support javascript.
loading
Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group.
Yanagisawa, Ryu; Tamaki, Masaharu; Tanoshima, Reo; Misaki, Yukiko; Uchida, Naoyuki; Koi, Satoshi; Tanaka, Takashi; Ozawa, Yukiyasu; Matsuo, Yayoi; Tanaka, Masatsugu; Ikegame, Kazuhiro; Katayama, Yuta; Matsuoka, Ken-Ichi; Ara, Takahide; Kanda, Yoshinobu; Matsumoto, Kimikazu; Fukuda, Takahiro; Atsuta, Yoshiko; Kato, Motohiro; Nakasone, Hideki.
Affiliation
  • Yanagisawa R; Division of Blood Transfusion, Shinshu University Hospital, Matsumoto, Japan.
  • Tamaki M; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Tanoshima R; Department of Pediatrics, Yokohama City University Hospital, Yokohama, Japan.
  • Misaki Y; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Uchida N; Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
  • Koi S; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Tanaka T; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Ozawa Y; Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
  • Matsuo Y; Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
  • Tanaka M; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
  • Ikegame K; Department of Hematology, Hyogo College of Medicine Hospital, Nishinomiya, Japan.
  • Katayama Y; Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
  • Matsuoka KI; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Ara T; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
  • Kanda Y; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Matsumoto K; Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
  • Fukuda T; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
  • Kato M; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.
  • Nakasone H; Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
Hematol Oncol ; 41(3): 535-545, 2023 Aug.
Article in En | MEDLINE | ID: mdl-36385399
ABSTRACT
Fatal cardiac complications can occur from the early to late phases after hematopoietic cell transplantation (HCT). Herein, the Japanese transplant registry database was used to retrospectively analyze health records of 33,791 allogeneic HCT recipients to elucidate the pathogenesis and risk factors involved. Overall, 527 patients died of cardiac complications at a median of 130 (range 0-3924) days after HCT. The cumulative incidence of fatal cardiac complications was 1.2% (95% confidence interval [CI] 1.0-1.3) and 1.6% (95% CI 1.5-1.8) at 1 and 5 years after HCT, respectively. Fatal cardiovascular events were significantly associated with an HCT-specific comorbidity index (HCT-CI) score of ≥1 specific to the three cardiovascular items, lower performance status, conditioning regimen cyclophosphamide dose of >120 mg/kg, and female sex. Cardiovascular death risk within 60 days after HCT was associated with the type of conditioning regimen, presence of bacterial or fungal infections at HCT, and number of blood transfusions. Contrastingly, late cardiovascular death beyond 1 year after HCT was associated with female sex and older age. Lower performance status and positive cardiovascular disease-related HCT-CI were risk factors for cardiac complications in all phases after HCT. Systematic follow-up may be necessary according to the patients' risk factors and conditions.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / East Asian People Type of study: Etiology_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / East Asian People Type of study: Etiology_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Year: 2023 Type: Article